Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus BSC vs BSC in metastatic colorectal cancer
NCT00113763Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2004
- Primary completion
- Oct 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal cancer (mCRC) comparing Panitumumab + BSC with Best Supportive Care (2 arms). Primary endpoint: Progression-free Survival Time. Started Jan 2004; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00113763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113763.